Displaying 13 - 24 of 24
Metabolism, Alcohol & Toxicity

To what extent can HRQoL impact clinical outcomes in MAFLD?

Webcasts
View
Metabolism, Alcohol & Toxicity

Essential phospholipids in the liver health landscape – clinical evidence

Webcasts
View
Metabolism, Alcohol & Toxicity

MAFLD – the importance of early identification and interventio

Webcasts
View
Metabolism, Alcohol & Toxicity

MAFLD-associated metabolic risks in obesity and diabetes – insights from clinical practice

Webcasts
View
Metabolism, Alcohol & Toxicity

Sanofi: "Global Liver Health Forum 2023 – Expert's exchange" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Q&A and panel discussion

Webcasts
View
Metabolism, Alcohol & Toxicity

Summary and closing remarks

Webcasts
View
Immune-Mediated and Cholestatic Diseases

CymaBay Therapeutics: "Resetting the ideal goals of PBC treatment: A case – based discussion"  (Complete Session)

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Introduction

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Case Based Discussion on Biochemical Normalization

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Case Based Discussion on QOL/Pruritus

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Conclusion

Webcasts
View
Displaying 13 - 24 of 24